InMode Ltd. — FY2023 Form 20-F Summary
Business context and reporting period
InMode designs and sells energy-based medical aesthetic devices and related consumables and services, with a focus on minimally invasive radio-frequency technologies. This is an audited annual report for the fiscal year ended December 31, 2023—not a quarterly filing. The provided filing does not give a clear standalone fourth-quarter income statement or cash-flow value, so Q4-specific performance cannot be assessed from this text.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $492.0 million | $454.3 million |
| Gross profit / margin | $411.3 million / 84% | $380.8 million / 84% |
| Operating income / margin | $195.7 million / 40% | $197.9 million / 44% |
| Net income | $197.9 million | $161.5 million |
| Basic / diluted EPS | $2.37 / $2.30 | $1.96 / $1.89 |
| Cash from operating activities | $176.8 million | $181.6 million |
- Revenue rose 8%. Net income increased 23%, while operating income declined about 1%; higher finance income and lower income taxes contributed to the net-income increase.
- Sales of minimally invasive platforms were $406.6 million, or 83% of revenue, versus $369.0 million, or 81%, in 2022. Consumables and service revenue was $80.0 million, up from $60.1 million.
- U.S. revenue was $307.8 million; revenue outside the U.S. was $184.2 million, or about 37% of total revenue. Europe contributed $62.5 million.
- Year-end cash and cash equivalents were $144.4 million, marketable securities $373.6 million and short-term bank deposits $223.5 million—about $741.6 million combined. Working capital was $781.2 million. The company reported no outstanding borrowings; total liabilities were $75.9 million.
- Investing cash outflow was $136.1 million, largely reflecting purchases and maturities of deposits and marketable securities. Financing cash inflow was $5.5 million, primarily from option exercises. Capital expenditures were $0.8 million.
Material changes versus the prior comparable period
- International revenue increased 18%, compared with 3% U.S. growth; management attributed overseas gains to added sales representatives, regional awareness and new subsidiaries.
- Sales and marketing expense increased 20% to $193.0 million, while total operating expenses rose 18% to $215.7 million. As a result, operating margin declined from 44% to 40% despite higher revenue and an unchanged 84% gross margin.
- Net finance income rose to $21.6 million from $3.6 million, principally due to higher interest income on investments and deposits and foreign-exchange movements.
- Income tax expense fell to $19.3 million from $39.9 million. The 2022 comparison included one-time Israeli tax payments and settlements, including approximately $12.0 million and $14.3 million payments described in the filing.
- Operating cash flow declined to $176.8 million from $181.6 million, with 2023 working-capital outflows including higher receivables and inventory.
Outlook, commentary, risks and unusual items
- No specific revenue or earnings guidance is provided. Management expects continued investment in sales capacity, R&D and new products, and anticipates 2024 capital expenditures of up to $1 million, funded from existing cash. It expects consumables and extended-warranty revenue to grow with the installed base and describes the fourth quarter as historically somewhat stronger, but says the business is not significantly seasonal.
- Management expects gross margin to be maintained at current levels if higher material and shipping costs can be offset by manufacturing efficiencies and pricing; it also expects R&D and sales and marketing expenses to increase in absolute dollars as the business expands.
- Israel-related operating risk is significant: headquarters, R&D and all three major manufacturing subcontractors are in Israel, with two subcontractors particularly important. The company said the war’s impact on FY2023 results and financial condition was immaterial, but warned that continued or expanded conflict could make the impact material. War-related losses may not be covered by commercial insurance.
- InMode outsources almost all manufacturing, relies on a limited supplier base and provides rolling forecasts. Subcontractor inventory, raw materials and open orders totaled about $41.6 million at year-end; advances securing these obligations were about $9.9 million.
- In October 2023, InMode filed a patent-infringement complaint against BTL Industries. The case was at an early stage in the filing. The company also identifies product-liability, regulatory-clearance, off-label marketing, competitive, cybersecurity, foreign-exchange and discretionary-spending risks.
- The company reported $21.6 million of net finance income and $23.6 million of share-based compensation expense in 2023. It has never paid cash dividends. It repurchased no shares in 2023; cumulative repurchases under its programs were 2.56 million shares for $95.2 million through year-end.
- The auditor issued an unqualified opinion on the financial statements and internal control over financial reporting; no critical audit matters were identified. Management reported effective disclosure controls and internal control at year-end.
Important facts for investors to verify
- Obtain the company’s quarterly filings or earnings releases to assess Q4 revenue, margins, earnings and cash flow; this annual filing does not provide clear standalone Q4 figures.
- Assess whether international growth, consumables and service revenue can offset slower U.S. growth and the concentration in minimally invasive platform sales.
- Review operating-expense growth and the extent to which investment-related finance income, rather than operating performance, supported 2023 net-income growth.
- Monitor receivables, inventory, collections and investment maturities, and confirm the liquidity and risk profile of the securities and deposits included in reported liquid resources.
- Track the Israel-Hamas war’s effects on staff availability, subcontractor capacity, regulatory inspections and shipments, as well as developments in the BTL patent litigation.
- Verify the application of Israeli tax incentives, future tax rates and any remaining obligations or contingencies; the filing describes a roughly 7.5% expected Israeli corporate tax rate under the applicable technology-enterprise regime.